postprandial

1-Deoxynojirimycin (Moranoline) is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

1-Deoxynojirimycin hydrochloride (Moranoline) is a potent and selective inhibitor of alpha-glucosidase, most commonly found in mulberry leaves. Duvoglustat is used to suppress the elevation of postprandial hyperglycemia.

ARRY-403 is a novel glucokinase activator that reduces fasting and postprandial blood glucose in patients with type 2 diabetes.

Casein is a milk protein with multiple roles in a novel drug delivery system that affects postprandial amino acid delivery in different ways through its intragastric coagulation properties.

AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1). IC50 value: 80 nM [1] Target: DGAT1 in vitro: Plasma AZD7687 exposure was measured repeatedly. AZD7687 markedly reduced postprandial TAG excursion with a steep concent

Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation.

α-glucosidase/PTP1B-IN-1 (compound 8a) is an effective inhibitor of both α-glucosidase and PTP1B, with IC50 values of 66.3 μM and 47.0 μM, respectively. It also exhibits strong inhibitory activity against α-amylase, having an IC50 of 30.62 μM. This compound is capable of binding to the active sites of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 holds potential for reducing postprandial blood glucose levels and may be useful in managing type 2 diabetes.

Cetagliptin is an orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) and CYP2D6, with an IC50 of 6 µM. It acts as a substrate for P-glycoprotein and helps reduce GLP-1 degradation, maintaining postprandial blood glucose levels. It is used in research for type 2 diabetes.

Resinacein L is an inhibitor of α-glucosidase with an IC50 of 0.635 mM. This compound can slow the digestion and absorption of carbohydrates, thereby reducing postprandial blood glucose levels.

α-Glucosidase-IN-88 (Compound 3K) is an orally active and potent α-glucosidase inhibitor with an IC50 value of 6.40 µM. It reduces postprandial blood glucose levels by inhibiting the hydrolysis of carbohydrates, preventing the enzyme from breaking glycosidic bonds. α-Glucosidase-IN-88 shows potential for research in type 2 diabetes mellitus (T2DM).

α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor with an IC50 of 4.32 μM, demonstrating acute blood-glucose-lowering properties. It is safe and effective in vivo, showing no toxicity to normal fibroblasts in mice and can ameliorate diabetes induced by streptozotocin in rats. α-Glucosidase-IN-43 is applicable for research on postprandial hyperglycemia in diabetic patients.

α-Glucosidase-IN-92 (compound 14b) is a non-competitive inhibitor targeting α-glucosidase with an IC50 of 64.0 μM, displaying greater inhibitory potency than Acarbose (IC50=750 μM). It has excellent oral bioavailability and can cross the blood-brain barrier. This compound slows carbohydrate hydrolysis and reduces postprandial blood glucose levels, making it useful for antidiabetic studies in type 2 diabetes.

α-Glucosidase-IN-98 is a potent orally active α-glucosidase inhibitor with an IC₅₀ value of 18.1 μM. It reversibly binds to α-glucosidase through hydrogen bonding, electrostatic interactions, and hydrophobic interactions, inducing significant conformational changes in the enzyme's secondary structure. This compound can reduce postprandial blood glucose levels in mice with starch/sucrose loads and is applicable in research related to type 2 diabetes (T2DM).

CP-800569 is an orally active inhibitor of cholesteryl ester transfer protein (CETP). It effectively reduces low-density lipoprotein and postprandial triglycerides while increasing high-density lipoprotein. CP-800569 is applicable in the study of metabolic diseases.

Enprostil is a synthetic PGE2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. It has efficient and safe in the therapy of gastroduodenal ulcers.

AZD-6370 is a glucokinase activator. AZD-6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. AZD-6370 do not affect the central counterregulatory response to hypoglycemia

WB403 is a TGR5 activator. WB403 significantly decreases fasting blood glucose, postprandial blood glucose and HbA1c, improves glucose tolerance in type 2 diabetic mice. WB403 increases pancreatic β-cells and restores the normal distribution pattern of α-

50F10 is a stabilizer for the active LPL dimer. It can act by preventing angptl4- and heat-induced inactivation of LPL and reducing postprandial triglyceride levels.

Trilobatin (P-Phlorizin) has anti-oxidant effect, can increase superoxide dismutase (SOD) activity.Trilobatin has anti-inflammatory effect, it potentially inhibits the lipopolysaccharide (LPS)-induced inflammatory response by suppressing the NF-κB signaling pathway.Trilobatin shows a strong inhibitory activity against α-glucosidase and a moderate inhibitory activity against α-amylase for management of postprandial hyperglycemia with less side effect.

Arbaclofen placarbil( XP19986) is a GABA(B) receptor agonist.Arbaclofen Placarbil is a novel R-baclofen prodrug with improved absorption, distribution, metabolism, and elimination properties compared to R-baclofen. And it can reduce postprandial reflux in

Massarigenin C is a fungal metabolite that has been found inM. flavoroseaand has enzyme inhibitory activities.1,2Massarigenin C inhibits neuraminidasein vitro(IC50= 4.15 μM).2It is also an inhibitor of yeast α-glucosidase (IC50= 1.25 mM).1It reduces the postprandial peak in blood glucose levels in an oral sucrose tolerance test in normo- and hyperglycemic mice when administered at doses of 3.2, 10, and 31.6 mg/kg.

Saxagliptin is a new oral hypoglycemic of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones and reducing fasting and postprandial glucose conce

(+/-)- Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Inhibition of glucagon signalling by LY2409021 is a promising potential treatment for patients with type 2 diabetes and should be evaluated in longer clinical trials to better evaluate benefits and risks.

D-(+)-Sorbose, the active enantiomer of D-Sorbose, inhibits disaccharidase activity and demonstrates suppressive effects on postprandial blood glucose and insulin levels in rats. Its role as a sweetener may aid in preventing lifestyle-related diseases, such as type 2 diabetes mellitus.